meta
|
evidence
oncology
Living systematic review and meta-analysis
metastatic glioblastoma (mGB) - 2nd line (L2)
head and neck cancer squamous cell cancer (HNSCC)
immune chekpoint inhibitors
anti-PD-(L)1
atezolizumab based treatment
atezolizumab alone
avelumab based treatment
avelumab alone
durvalumab based treatment
durvalumab alone
finotonlimab (SCT-I10A)
nivolumab based treatment
nivolumab alone
nivolumab plus epacadostat
pembrolizumab based treatment
pembrolizumab alone
pembrolizumab plus 5FU plus platin
retifanlimab plus enoblituzumab
Immune checkpoint association
durvalumab plus tremelimumab
nivolumab plus ipilimumab
Immunostimulant
IRX-2
versus all
vs chemotherapy
vs platinum-based chemotherapy
vs platinum derivate
vs cisplatin
vs Standard of Care (SoC)
vs HER inhibitor
vs EGFR inhibitor
vs cetuximab based chemotherapy
vs cetuximab alone
vs cetuximab plus platin plus 5FU
vs immune chekpoint inhibitors
vs anti-CTLA-4
vs tremelimumab
vs anti-PD-(L)1
vs durvalumab based treatment
vs durvalumab alone
vs pembrolizumab based treatment
vs pembrolizumab alone
vs non active control
vs no additional treatment
vs placebo
study list
mapping
overview
meta-analysis
forest plot
NMA
excluded
graph
table
EGM
comparisons
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
click on circles to display study description...
powered by
vis.js Network